BioPharmSignal logoBioPharmSignal

Biotech News

Nkarta Announces FDA Agreement on Outpatient Dosing of NKX019 in Autoimmune Disease, Expanding Access to Community Rheumatology Centers

Nkarta (NKTX)NkartaFDA / regulatory

Expanded treatment in community settings will reduce patient burden Option to redose patients granted in both Ntrust-1 and Ntrust-2 studies Rheumatoid arthritis cohort to be added to Ntrust-2 Dosing continues at 4 billion cell dose level (12 billion cells in 3-dose cycle) with initial data expected

Related news

NKTXNkarta2026-09-08 11:00 EST

Nkarta to Present Initial Autoimmune Clinical Data for NKX019 at American College of Rheumatology (ACR) Convergence 2026

ERASErasca2026-08-24 12:00 EST

Erasca Granted FDA Fast Track Designation for Pan-RAS Molecular Glue ERAS-0015 in Patients with Metastatic Pancreatic Adenocarcinoma

BMYBMYBristol-Myers Squibb Company2026-08-13 21:12 EST

U.S. FDA Grants Accelerated Approval to Bristol Myers Squibb's First CELMoD Therapy ZENBEXUS™, in Combination with Daratumumab and Hyaluronidase-fihj and Dexamethasone (ZDd) for Patients with Multiple Myeloma, as Early as First Relapse

COGTCogent Biosciences2026-09-15 12:00 EST

Cogent Biosciences Announces FDA Acceptance of New Drug Application (NDA) for Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)

RVMDRevolution Medicines2026-08-26 16:59 EST

U.S. FDA Approves Revolution Medicines’ RASONQUE™ (daraxonrasib), the First Broad RAS-Targeted Medicine in Metastatic Pancreatic Cancer

NKTXNkarta2026-08-10 20:24 EST

Nkarta Reports Second Quarter 2026 Financial Results and Corporate Highlights

RVMDRevolution Medicines2026-09-14 20:05 EST

Revolution Medicines Announces U.S. FDA Breakthrough Therapy Designation for RASONQUE™ (daraxonrasib) in Combination with Chemotherapy for First Line Metastatic Pancreatic Cancer

TEVATeva Pharmaceutical Industries2026-08-28 10:17 EST

Teva Announces Proposed Acquisition of a Novel Neuroscience Product Reinforcing Disciplined Business Development Approach Under Pivot to Growth Strategy

GSKGSK plc2026-08-24 07:01 EST

Jemperli (dostarlimab) accepted for priority review by the US FDA for dMMR/MSI-H locally advanced rectal cancer

REGNRegeneron Pharmaceuticals2026-08-19 17:58 EST

Pasatru™ (garetosmab-grts) First and Only FDA-approved Treatment Demonstrating Reduction in New Heterotopic Ossification (HO) Lesions and Clinician-Assessed Flare-ups in a Placebo-controlled Trial in Adults with Fibrodysplasia Ossificans Progressiva (FOP)

View all latest news

Nkarta

Allogeneic CAR-NK Company Nkarta develops off-the-shelf natural killer cell therapies for autoimmune disease and cancer. NKX019 NKX019 is a CD19-directed CAR-NK therapy designed to deplete pathogenic B cells without patient-specific manufacturing. Ntrust Studies Ntrust-1 and Ntrust-2 evaluate NKX019 across autoimmune diseases with...

Recent company news

NKTXNkarta2026-09-10 11:00 EST

Nkarta to Participate in September Investor Conferences

NKTXNkarta2026-09-08 11:00 EST

Nkarta to Present Initial Autoimmune Clinical Data for NKX019 at American College of Rheumatology (ACR) Convergence 2026

NKTXNkarta2026-08-10 20:24 EST

Nkarta Reports Second Quarter 2026 Financial Results and Corporate Highlights

NKTXNkarta2026-05-12 20:01 EST

Nkarta Reports First Quarter 2026 Financial Results and Corporate Highlights

NKTXNkarta2026-04-15 20:01 EST

Nkarta Announces FDA Agreement on Outpatient Dosing of NKX019 in Autoimmune Disease, Expanding Access to Community Rheumatology Centers

Stock data

Close
2.56 USD
Market cap
208.2M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States